Pheon rides wave of ADC interest with $120M financing | BioPharma Dive

Retrieved on: 2024-05-21 16:36:08

Tags for this article:

Biotechnology

Antineoplastic drugs

Immunology

Antibody-drug conjugate

Atlas Venture

Pheon Therapeutics

Click the tags to see associated articles and topics

Pheon rides wave of ADC interest with $120M financing | BioPharma Dive. View article details on hiswai:

Summary

The article discusses Pheon Therapeutics, a British biotechnology startup, raising $120 million in funding to advance antibody-drug conjugates (ADCs) for cancer treatment, emphasizing their innovative approach in developing targeted antineoplastic drugs. The key concept 'biopharma' connects the company's efforts in biotechnology, immunology, and venture backing from firms like Atlas Venture.

Article found on: www.biopharmadive.com

View Original Article